USD 5.09
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| CLVT | 0 | 1.0 | 1.8 | -24.0 | -20.6 | -43.6 | -69.5 | -73.7 | -47.0 | -47.0 |
| S&P 500 | 1.0 | 3.7 | 2.1 | 2.3 | 8.2 | 25.4 | 31.0 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | CLVT |
| name | Clarivate Plc |
| price | 5.09 |
| changes percentage | 0 |
| change | 0 |
| day low | 5.005 |
| day high | 5.19 |
| year high | 9.61 |
| year low | 4.25 |
| market cap | 3615956360 |
| price avg 50 | 5.2074 |
| price avg 200 | 6.11015 |
| exchange | NYSE |
| volume | 2403386 |
| avg volume | 5444218 |
| open | 5.16 |
| previous close | 5.09 |
| eps | -1.98 |
| pe | -2.57 |
| earnings announcement | 2025-02-25T13:30:00.000+0000 |
| shares outstanding | 710404000 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001764046 | |||
| revenue | 2628800000 | 2659800000 | -1.17 |
| gross profit | 1722400000 | 1705800000 | 0.97 |
| gross profit ratio | 0.66 | 0.64 | 2.16 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 2457100000 | 1115600000 | 120.25 |
| interest income | 0 | 270300000 | -100.00 |
| interest expense | 293700000 | 270300000 | 8.66 |
| ebitda | -10500000 | -3008300000 | 99.65 |
| ebitdaratio | -0.0 | 0.49 | -100.82 |
| operating income | -734700000 | -3925600000 | 81.28 |
| operating income ratio | -0.28 | -1.48 | 81.06 |
| net income | -911200000 | -3960200000 | 76.99 |
| net income ratio | -0.35 | -1.49 | 76.72 |
| eps | -1.47 | -5.86 | 74.91 |
Revenue Growth: revenue decreased to 2,629 million in 2023 from 2,660 million in 2022 representing a change of -1.17%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 2,457 million in 2023 from 1,116 million in 2022 representing a change of 120.25%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -10 million in 2023 from -3,008 million in 2022 representing a change of 99.65%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Gross Profit: Gross Profit increased to 1,722 million in 2023 from 1,706 million in 2022 representing a change of 0.97%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Income: Operating income increased to -735 million in 2023 from -3,926 million in 2022 representing a change of 81.28%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -911 million in 2023 from -3,960 million in 2022 representing a change of 76.99%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -1.47 in 2023 from -1.47 in 2022 representing a change of 74.91%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001764046 | |||
| revenue | 622200000 | 650300000 | -4.32 |
| gross profit | 412100000 | 252300000 | 63.34 |
| gross profit ratio | 0.66 | 0.39 | 70.71 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 390400000 | 185200000 | 110.80 |
| interest income | 0 | 0 | NaN |
| interest expense | 72200000 | 71100000 | 1.55 |
| ebitda | 198900000 | -68100000 | 392.07 |
| ebitdaratio | 0.32 | 0.39 | -17.34 |
| operating income | 21700000 | 67099999 | -67.66 |
| operating income ratio | 0.03 | 0.1 | -66.20 |
| net income | -65600000 | -304300000 | 78.44 |
| net income ratio | -0.11 | -0.47 | 77.47 |
| eps | -0.09 | -0.44 | 79.25 |
Revenue Growth: revenue decreased to 622 million in 2024Q3 from 650 million in 2024Q2 representing a change of -4.32%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 390 million in 2024Q3 from 185 million in 2024Q2 representing a change of 110.8%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to 22 million in 2024Q3 from 67 million in 2024Q2 representing a change of -67.66%. The decrease in operating income indicates worse operational performance and decreased profitability.
Gross Profit: Gross Profit increased to 412 million in 2024Q3 from 252 million in 2024Q2 representing a change of 63.34%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 199 million in 2024Q3 from -68 million in 2024Q2 representing a change of 392.07%. The increase in EBITDA indicates improved operational efficiency and profitability.
Net Income: Net income increased to -66 million in 2024Q3 from -304 million in 2024Q2 representing a change of 78.44%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.09 in 2024Q3 from -0.09 in 2024Q2 representing a change of 79.25%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001764046 | |||
| total assets | 12706800000 | 13944900000 | -8.88 |
| total liabilities | 6714500000 | 7132400000 | -5.86 |
| total equity | 5992300000 | 6812500000 | -12.04 |
| cash and cash equivalents | 370700000 | 348800000 | 6.28 |
| short term investments | 0 | 2300000 | -100.00 |
| long term investments | 17700000 | 47200000 | -62.50 |
| total current assets | 1462200000 | 1395200000 | 4.80 |
| total non current assets | 11244600000 | 12549700000 | -10.40 |
| total current liabilities | 1600000000 | 1559800000 | 2.58 |
| total non current liabilities | 5114500000 | 5572600000 | -8.22 |
| common stock | 11740500000 | 11744700000 | -0.04 |
| retained earnings | -6645500000 | -5658900000 | -17.43 |
| total debt | 4808700000 | 5104600000 | -5.80 |
Total Assets: Total Assets decreased to 12,707 million in 2023 from 13,945 million in 2022 representing a change of -8.88%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 5,992 million in 2023 from 6,812 million in 2022 representing a change of -12.04%. This indicates a decrease in shareholders' equity.
Short Term Investments: Short Term Investments decreased to 0 million in 2023 from 2 million in 2022 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 1,600 million in 2023 from 1,560 million in 2022 representing a change of 2.58%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 11,740 in 2023 from 11,745 in 2022 representing a change of -0.04%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -6,646 million in 2023 from -5,659 million in 2022 representing a change of -17.43%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 6,714 million in 2023 from 7,132 million in 2022 representing a change of -5.86%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 371 million in 2023 from 349 million in 2022 representing a change of 6.28%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 1,462 million in 2023 from 1,395 million in 2022 representing a change of 4.8%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 4,809 million in 2023 from 5,105 million in 2022 representing a change of -5.8%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001764046 | |||
| total assets | 12030600000 | 12077700000 | -0.39 |
| total liabilities | 6517100000 | 6473100000 | 0.68 |
| total equity | 5513500000 | 5604600000 | -1.63 |
| cash and cash equivalents | 388500000 | 376400000 | 3.21 |
| short term investments | 0 | 0 | NaN |
| long term investments | 7400000 | 26000000 | -71.54 |
| total current assets | 1339100000 | 1334800000 | 0.32 |
| total non current assets | 10691500000 | 10742900000 | -0.48 |
| total current liabilities | 1525600000 | 1485100000 | 2.73 |
| total non current liabilities | 4991500000 | 4988000000 | 0.07 |
| common stock | 13069000000 | 13157700000 | -0.67 |
| retained earnings | -7121700000 | -7056100000 | -0.93 |
| total debt | 4712500000 | 4731300000 | -0.40 |
Total Assets: Total Assets decreased to 12,031 million in 2024Q3 from 12,078 million in 2024Q2 representing a change of -0.39%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 6,517 million in 2024Q3 from 6,473 million in 2024Q2 representing a change of 0.68%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 5,514 million in 2024Q3 from 5,605 million in 2024Q2 representing a change of -1.63%. This indicates a decrease in shareholders' equity.
Total Current Liabilities: Total Current Liabilities increased to 1,526 million in 2024Q3 from 1,485 million in 2024Q2 representing a change of 2.73%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 13,069 in 2024Q3 from 13,158 in 2024Q2 representing a change of -0.67%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -7,122 million in 2024Q3 from -7,056 million in 2024Q2 representing a change of -0.93%. This indicates an accumulated losses.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 388 million in 2024Q3 from 376 million in 2024Q2 representing a change of 3.21%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 1,339 million in 2024Q3 from 1,335 million in 2024Q2 representing a change of 0.32%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 4,712 million in 2024Q3 from 4,731 million in 2024Q2 representing a change of -0.4%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001764046 | |||
| net change in cash | 13900000 | -230800000 | 106.02 |
| operating cash flow | 744200000 | 509300000 | 46.12 |
| free cash flow | 501700000 | 306400000 | 63.74 |
| capital expenditure | -242500000 | -202900000 | -19.52 |
| depreciation and amortization | 708300000 | 710500000 | -0.31 |
| deferred income tax | -78400000 | -54300000 | -44.38 |
| stock based compensation | 109000000 | 93900000 | 16.08 |
| accounts payables | 41200000 | -24000000 | 271.67 |
| inventory | 0 | -210300000 | 100.00 |
| acquisitions net | 5100000 | 260200000 | -98.04 |
| investments in property plant and equipment | -242500000 | -202900000 | -19.52 |
| net cash used for investing activites | -237400000 | 57300000 | -514.31 |
| debt repayment | -301000000 | -498400000 | 39.61 |
| common stock issued | 0 | 5700000 | -100.00 |
| common stock repurchased | -100000000 | -175000000 | 42.86 |
| dividends paid | -75500000 | -75400000 | -0.13 |
| net cash used provided by financing activities | -496500000 | -759200000 | 34.60 |
| cash at end of period | 370700000 | 356800000 | 3.90 |
| accounts receivables | -25500000 | -28300000 | 9.89 |
| cash at beginning of period | 356800000 | 587600000 | -39.28 |
Net Change in Cash: Net Change in Cash increased to 14 million in 2023 from -231 million in 2022 representing a change of 106.02%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 744 million in 2023 from 509 million in 2022 representing a change of 46.12%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 502 million in 2023 from 306 million in 2022 representing a change of 63.74%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -242 million in 2023 from -203 million in 2022 representing a change of -19.52%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation increased to 109 million in 2023 from 94 million in 2022 representing a change of 16.08%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 41 million in 2023 from 24 million in 2022 representing a change of 271.67%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to -26 in 2023 from -28 million in 2022 representing a change of 9.89%. This suggests that the company is less capable of collecting payments from its customers.
Dividends Paid: Dividends Paid decreased to -76 million in 2023 from -75 million in 2022 representing a change of -0.13%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001764046 | |||
| operating cash flow | 202900000 | 126000000 | 61.03 |
| free cash flow | 126300000 | 60100000 | 110.15 |
| capital expenditure | -76600000 | -65900000 | -16.24 |
| depreciation and amortization | 177200000 | 184400000 | -3.90 |
| deferred income tax | -4200000 | -24600000 | 82.93 |
| stock based compensation | 15000000 | 18900000 | -20.63 |
| accounts receivables | 45000000 | 28400000 | 58.45 |
| accounts payables | -4300000 | 25100000 | -117.13 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 4300000 | -36300000 | 111.85 |
| investments in property plant and equipment | -76600000 | -65900000 | -16.24 |
| net cash used for investing activites | -91500000 | -102200000 | 10.47 |
| debt repayment | -5700000 | -5400000 | -5.56 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -100000000 | -1300000 | -7592.31 |
| dividends paid | 0 | -18800000 | 100.00 |
| net cash used provided by financing activities | -109700000 | -25400000 | -331.89 |
| net change in cash | 12100000 | 14600000 | -17.12 |
| cash at end of period | 388500000 | 376400000 | 3.21 |
| cash at beginning of period | 376400000 | 361800000 | 4.04 |
Net Change in Cash: Net Change in Cash decreased to 12 million in 2024Q3 from 15 million in 2024Q2 representing a change of -17.12%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Deferred Income Tax: Deferred Income Tax increased to -4 million in 2024Q3 from -25 million in 2024Q2 representing a change of 82.93%. This indicates that the company's tax liability for future periods has increased.
Accounts Receivables: Accounts Receivables increased to 45 in 2024Q3 from 28 million in 2024Q2 representing a change of 58.45%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to 203 million in 2024Q3 from 126 million in 2024Q2 representing a change of 61.03%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 126 million in 2024Q3 from 60 million in 2024Q2 representing a change of 110.15%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -77 million in 2024Q3 from -66 million in 2024Q2 representing a change of -16.24%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 15 million in 2024Q3 from 19 million in 2024Q2 representing a change of -20.63%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 4 million in 2024Q3 from 25 million in 2024Q2 representing a change of -117.13%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Dividends Paid: Dividends Paid increased to 0 million in 2024Q3 from -19 million in 2024Q2 representing a change of 100.0%. This indicates a stronger financial position, more confidence in future prospects, and a better commitment to returning value to shareholders.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 3.91 | 3.93 | -0.50 |
| net income per share | -1.36 | -5.86 | 76.84 |
| operating cash flow per share | 1.11 | 0.75 | 47.10 |
| free cash flow per share | 0.75 | 0.45 | 64.84 |
| cash per share | 0.55 | 0.52 | 6.29 |
| book value per share | 8.92 | 10.08 | -11.45 |
| tangible book value per share | -7.5 | -8.14 | 7.81 |
| shareholders equity per share | 8.92 | 10.08 | -11.45 |
| interest debt per share | 7.6 | 7.95 | -4.43 |
| market cap | 6219016000 | 5638674000 | 10.29 |
| enterprise value | 10657016000 | 10394474000 | 2.53 |
| pe ratio | -6.83 | -1.42 | -379.34 |
| price to sales ratio | 2.37 | 2.12 | 11.59 |
| pocfratio | 8.36 | 11.07 | -24.52 |
| pfcf ratio | 12.4 | 18.4 | -32.64 |
| pb ratio | 1.04 | 0.83 | 25.39 |
| ptb ratio | 1.04 | 0.83 | 25.39 |
| ev to sales | 4.05 | 3.91 | 3.73 |
| enterprise value over ebitda | -1014.95 | -3.46 | -29274.13 |
| ev to operating cash flow | 14.32 | 20.41 | -29.84 |
| ev to free cash flow | 21.24 | 33.92 | -37.39 |
| earnings yield | -0.15 | -0.7 | 79.14 |
| free cash flow yield | 0.08 | 0.05 | 48.46 |
| debt to equity | 0.8 | 0.75 | 7.10 |
| debt to assets | 0.38 | 0.37 | 3.38 |
| net debt to ebitda | -422.67 | -1.58 | -26635.95 |
| current ratio | 0.91 | 0.89 | 2.17 |
| interest coverage | -2.5 | -14.52 | 82.78 |
| income quality | -0.82 | -0.13 | -535.07 |
| dividend yield | 0.01 | 0.01 | -9.21 |
| payout ratio | -0.08 | -0.02 | -335.19 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.87 | 0.88 | -1.70 |
| capex to operating cash flow | 0.33 | 0.4 | -18.21 |
| capex to revenue | 0.09 | 0.08 | 20.93 |
| capex to depreciation | 0.34 | 0.29 | 19.89 |
| stock based compensation to revenue | 0.04 | 0.04 | 17.45 |
| graham number | 16.5 | 36.44 | -54.71 |
| roic | -0.06 | -0.31 | 81.08 |
| return on tangible assets | -0.54 | -2.43 | 77.62 |
| graham net net | -8.43 | -8.99 | 6.22 |
| working capital | -137800000 | -164600000 | 16.28 |
| tangible asset value | -5038000000 | -5501700000 | 8.43 |
| net current asset value | -5252300000 | -5737200000 | 8.45 |
| invested capital | 10999300000 | 12263000000 | -10.30 |
| average receivables | 890200000 | 889250000 | 0.11 |
| average payables | 122750000 | 115299999.5 | 6.46 |
| average inventory | 48700000 | 97400000 | -50.00 |
| days sales outstanding | 126.11 | 119.68 | 5.38 |
| days payables outstanding | 58.03 | 38.8 | 49.57 |
| days of inventory on hand | 0 | 37.27 | -100.00 |
| receivables turnover | 2.89 | 3.05 | -5.10 |
| payables turnover | 6.29 | 9.41 | -33.14 |
| inventory turnover | 0 | 9.79 | -100.00 |
| roe | -0.15 | -0.58 | 73.84 |
| capex per share | 0.36 | 0.3 | 20.32 |
ROE: Return on Equity (ROE) increased to -0.15 on 2023-12-31 from -0.58 on 2022-12-31, representing a change of 73.84%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -6.83 on 2023-12-31 from -1.42 on 2022-12-31, representing a change of -379.34%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 0.91 on 2023-12-31 from 0.89 on 2022-12-31, representing a change of 2.17%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. However, it's below 1, indicating potential liquidity issues.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.80 on 2023-12-31 from 0.75 on 2022-12-31, representing a change of 7.10%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| CLVT | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.87 | 0.95 | -8.73 |
| net income per share | -0.09 | -0.44 | 79.44 |
| operating cash flow per share | 0.28 | 0.18 | 53.62 |
| free cash flow per share | 0.18 | 0.09 | 100.47 |
| cash per share | 0.54 | 0.55 | -1.54 |
| book value per share | 7.67 | 8.17 | -6.16 |
| tangible book value per share | -6.89 | -7.15 | 3.70 |
| shareholders equity per share | 7.67 | 8.17 | -6.16 |
| interest debt per share | 6.66 | 7.0 | -4.96 |
| market cap | 5102770000 | 3791368000 | 34.59 |
| enterprise value | 9426770000 | 8146268000 | 15.72 |
| pe ratio | -19.45 | -3.11 | -524.32 |
| price to sales ratio | 8.2 | 5.83 | 40.67 |
| pocfratio | 25.15 | 30.09 | -16.42 |
| pfcf ratio | 40.4 | 63.08 | -35.96 |
| pb ratio | 0.93 | 0.68 | 36.81 |
| ptb ratio | 0.93 | 0.68 | 36.81 |
| ev to sales | 15.15 | 12.53 | 20.95 |
| enterprise value over ebitda | 47.39 | -119.62 | 139.62 |
| ev to operating cash flow | 46.46 | 64.65 | -28.14 |
| ev to free cash flow | 74.64 | 135.55 | -44.94 |
| earnings yield | -0.01 | -0.08 | 83.98 |
| free cash flow yield | 0.02 | 0.02 | 56.14 |
| debt to equity | 0.85 | 0.84 | 1.25 |
| debt to assets | 0.39 | 0.39 | -0.01 |
| net debt to ebitda | 21.74 | -63.95 | 134.00 |
| current ratio | 0.88 | 0.9 | -2.34 |
| interest coverage | 0.3 | 0.94 | -68.15 |
| income quality | -3.09 | -0.41 | -646.98 |
| dividend yield | 0 | 0.0 | -100.00 |
| payout ratio | 0 | -0.06 | 100.00 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.87 | 0.87 | -0.03 |
| capex to operating cash flow | 0.38 | 0.52 | -27.82 |
| capex to revenue | 0.12 | 0.1 | 21.49 |
| capex to depreciation | 0.43 | 0.36 | 20.96 |
| stock based compensation to revenue | 0.02 | 0.03 | -17.05 |
| graham number | 3.97 | 9.04 | -56.07 |
| roic | 0.0 | 0.01 | -56.50 |
| return on tangible assets | -0.04 | -0.19 | 78.40 |
| graham net net | -7.72 | -8.02 | 3.73 |
| working capital | -186500000 | -150300000 | -24.09 |
| tangible asset value | -4950000000 | -4903200000 | -0.95 |
| net current asset value | -5178000000 | -5138300000 | -0.77 |
| invested capital | 10382400000 | 10451700000 | -0.66 |
| average receivables | 784050000 | 809600000 | -3.16 |
| average payables | 127300000 | 115400000 | 10.31 |
| average inventory | 0 | 69100000 | -100.00 |
| days sales outstanding | 111.64 | 110.21 | 1.30 |
| days payables outstanding | 54.19 | 28.97 | 87.07 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0.81 | 0.82 | -1.28 |
| payables turnover | 1.66 | 3.11 | -46.54 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.01 | -0.05 | 78.09 |
| capex per share | 0.11 | 0.1 | 10.88 |
ROE: Return on Equity (ROE) increased to -0.01 on 2024-09-30 Q3 from -0.05 on 2024-06-30 Q2, representing a change of 78.09%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -19.45 on 2024-09-30 Q3 from -3.11 on 2024-06-30 Q2, representing a change of -524.32%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.88 on 2024-09-30 Q3 from 0.90 on 2024-06-30 Q2, representing a change of -2.34%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.85 on 2024-09-30 Q3 from 0.84 on 2024-06-30 Q2, representing a change of 1.25%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Positive Sentiment: Discounted Cash Flow value is 14.88 which is higher than current price 5.09, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-16 11:01:25
The average of price targets set by Wall Street analysts indicates a potential upside of 29.1% in Clarivate (CLVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sentiment: Positive
Publish Date: 2025-01-16 03:00:00
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON , Jan. 16, 2025 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while forecasting key developments for 2025.
Sentiment: Neutral
Publish Date: 2025-01-14 11:40:00
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Post-marketing Pharmacovigilance and Medical Information Market by Type by Service, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The global post-marketing pharmacovigilance and medical information market size was estimated to be USD 6.22 billion in 2023 and is expected to reach USD 16.99 billion by 2034 with a CAGR of 9.56% during the forecast period 2024-2034.
Sentiment: Positive
Publish Date: 2025-01-14 03:10:00
New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON , Jan. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understand and act in varied disease and competitive landscapes — eliminating the complexities of raw data management.
Sentiment: Positive
Publish Date: 2025-01-08 03:05:00
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON , Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years.
Sentiment: Positive
Publish Date: 2024-12-16 08:00:00
LONDON , Dec. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that its Board of Directors (the "Board") authorized a new share repurchase program of up to $500 million of the Company's outstanding ordinary shares through open-market purchases for a period of two years, from January 1, 2025 through December 31, 2026. The new share repurchase program replaces the current share repurchase program which terminates December 31, 2024, under which the Company repurchased $300 million of ordinary shares, including $200 million during the third and fourth quarters of 2024.
Sentiment: Positive
Publish Date: 2024-12-12 03:00:00
Faster and more relevant results to empower critical IP decision-making LONDON , Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwentâ„¢. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)â„¢, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in less time.
Sentiment: Positive
Publish Date: 2024-12-10 08:00:20
It's widely believed that insiders know how well a company is operating. Therefore, when insiders are actively buying their stock, it is assumed they must know something that's motivating them to buy shares.
Sentiment: Positive
Publish Date: 2024-11-27 08:00:00
Revealing highly active specialties in sciences and social sciences LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Frontsâ„¢, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today.
Sentiment: Positive
Publish Date: 2024-11-27 03:00:00
Enhancing operational efficiency for leading air conditioner manufacturer LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Daikin Industries, Ltd. (Daikin) has selected IPfolio™ from Clarivate.
Sentiment: Positive
Publish Date: 2024-11-21 03:00:00
New seven-part series explores disparities in care, funding and innovation impacting half the world's population LONDON , Nov. 21, 2024 /PRNewswire/ -- BioWorld ™ published by Clarivate Plc  (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, 'Healing the Health Divide. ' This seven-part series sheds light on the persistent disparities in women's health research, funding, and treatment.
Sentiment: Positive
Publish Date: 2024-11-19 03:00:00
Prioritizing research integrity with enhanced filters to address publication and citation manipulation LONDON , Nov. 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scientific Information (ISI)™ have recognized 6,636 Highly Cited Researchers in 2024 from more than 1,200 institutions in 59 nations and regions.
Sentiment: Positive
Publish Date: 2024-11-18 03:00:00
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON , Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come . Over the past decade, Mainland China's biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches.
Sentiment: Positive
Publish Date: 2024-11-13 03:00:00
Recognizing Roper St. Francis Healthcare, Bon Secours Mercy Health, and Bronson Methodist Hospital for excellence in Physician and Hospital Groups LONDON , Nov. 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the 2023 winners of the Clarivate Healthcare Business Insights™ annual Revenue Cycle Awards. Now in its 12th year, the Revenue Cycle Awards recognize U.S.-based healthcare organizations for exceptional performance on revenue cycle KPIs, based on data from their most recent and preceding full fiscal years.
Sentiment: Positive
Publish Date: 2024-11-12 03:00:00
LONDON , Nov. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has today published its fourth annual sustainability report, showcasing its commitment to sustainability and the United Nations Sustainable Development Goals (SDGs). In 2023, Clarivate was shortlisted for the SDG Pioneer Award at the Thomson Reuters Responsible Business Awards.
Sentiment: Neutral
Publish Date: 2024-11-08 08:04:35
I downgrade Clarivate PLC from buy to hold due to lack of confidence in near-term organic growth recovery and potential further stock price decline. CLVT's 3Q24 earnings report showed a 3.9% revenue decline and worsening organic growth, marking the worst performance in its history. The new CEO's Value Creation Plan is promising but will take a long time to show results, adding to the uncertainty.
Sentiment: Positive
Publish Date: 2024-11-07 03:00:00
ProQuest One Sustainability offers a transdisciplinary research experience and features AI-powered ProQuest Research Assistant LONDON , Nov. 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of ProQuestTM One Sustainability. The new solution is an expansive, curated, multi-format content collection designed to meet the growing demand for sustainability curricula across research, teaching and learning.
Sentiment: Positive
Publish Date: 2024-11-06 15:07:46
Clarivate Plc (NYSE:CLVT ) Q3 2024 Earnings Conference Call November 6, 2024 9:00 AM ET Company Participants Mark Donohue - Vice President of Investor Relations Matti Shem Tov - Chief Executive Officer Jonathan Collins - Chief Financial Officer Conference Call Participants Owen Lau - Oppenheimer David Paige - RBC Toni Kaplan - Morgan Stanley Andrew Nicholas - William Blair Manav Patnaik - Barclays Shlomo Rosenbaum - Stifel Peter Christiansen - Citi George Tong - Goldman Sachs Colton Feldmann - Jefferies Operator Hello, and thank you for standing by. My name is Regina and I will be your conference operator today.
Sentiment: Positive
Publish Date: 2024-11-06 10:35:47
The headline numbers for Clarivate (CLVT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sentiment: Positive
Publish Date: 2024-11-06 08:10:22
Clarivate PLC (CLVT) came out with quarterly earnings of $0.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.21 per share a year ago.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
